- Home
- TPST vs NEPH Comparison
TPST vs NEPH Comparison
Compare TPST & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- NEPH
- Stock Information
- Founded
- TPST 2011
- NEPH 1997
- Country
- TPST United States
- NEPH United States
- Employees
- TPST N/A
- NEPH N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- NEPH Medical/Dental Instruments
- Sector
- TPST Health Care
- NEPH Health Care
- Exchange
- TPST Nasdaq
- NEPH Nasdaq
- Market Cap
- TPST 33.0M
- NEPH 37.4M
- IPO Year
- TPST N/A
- NEPH 2004
- Fundamental
- Price
- TPST $7.76
- NEPH $3.57
- Analyst Decision
- TPST Hold
- NEPH Buy
- Analyst Count
- TPST 3
- NEPH 1
- Target Price
- TPST $30.00
- NEPH $5.00
- AVG Volume (30 Days)
- TPST 80.4K
- NEPH 31.3K
- Earning Date
- TPST 08-07-2025
- NEPH 08-07-2025
- Dividend Yield
- TPST N/A
- NEPH N/A
- EPS Growth
- TPST N/A
- NEPH N/A
- EPS
- TPST N/A
- NEPH 0.08
- Revenue
- TPST N/A
- NEPH $15,517,000.00
- Revenue This Year
- TPST N/A
- NEPH $17.06
- Revenue Next Year
- TPST N/A
- NEPH $12.20
- P/E Ratio
- TPST N/A
- NEPH $47.02
- Revenue Growth
- TPST N/A
- NEPH 10.34
- 52 Week Low
- TPST $5.35
- NEPH $1.36
- 52 Week High
- TPST $28.34
- NEPH $5.00
- Technical
- Relative Strength Index (RSI)
- TPST 63.65
- NEPH 48.58
- Support Level
- TPST $6.11
- NEPH $3.35
- Resistance Level
- TPST $6.49
- NEPH $3.81
- Average True Range (ATR)
- TPST 0.35
- NEPH 0.27
- MACD
- TPST 0.03
- NEPH -0.06
- Stochastic Oscillator
- TPST 100.00
- NEPH 31.43
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.